Jazz Pharmaceuticals PLC (JAZZ) Actualités

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference PR Newswire DUBLIN, Nov. 19...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results PR Newswire DUBLIN, Nov. 6, 2024 – 14...

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium...

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024 PR Newswire DUBLIN...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival...

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival...

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in...

Form 4 - Statement of changes in beneficial ownership of securities